Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP9 | P14780 | 5/20 | 0.33 |
| ▸ | MMP13 | P45452 | 5/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP7 | P09237 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974092 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL1570351 | 0.81 | NPSR1 (0.47) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL3970900 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL7050294 | 0.78 | ADAMTS4 (0.40) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL8908871 | 0.73 | KDM4E (0.36) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL28001091 | 0.71 | GAA (0.45) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL28001099 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL6291990 | 0.70 | GAA (0.40) | SMN1; SMN2ALDH1A1MMP3NPSR1 | |
| SCHEMBL167548 | 0.70 | SMN1; SMN2 (0.58) | SMN1; SMN2CA2CA9ALDH1A1CA12 | |
| SCHEMBL2104884 | 0.69 | ALDH1A1 (0.62) | CA2CA9ALDH1A1CA12TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| US-7495040-B2 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080012918-A1 | Actinic Radiation Curable Ink-Jet Ink, And Image Forming Method And Ink-Jet Recording Apparatus Using The Same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050196697-A1 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050165123-A1 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | SMN1; SMN2 305/4885CA2 1603/4885CA9 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.